About: Geldanamycin, a ligand of heat shock protein 90, inhibits herpes simplex virus type 2 replication both in vitro and in vivo

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Geldanamycin, a ligand of heat shock protein 90, inhibits herpes simplex virus type 2 replication both in vitro and in vivo Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Geldanamycin, a ligand of heat shock protein 90, inhibits herpes simplex virus type 2 replication both in vitro and in vivo
Creator	Jiang, Jian-Dong Li, Yu-Huan Tao, Pei-Zhen Lu, Qiao-Ni Wang, Hui-Qiang
Source	Medline; PMC
abstract	Previously, we discovered geldanamycin, a ligand of heat shock protein 90, effectively inhibited herpes simplex virus type 1 replication in vitro and in vivo (mouse encephalitis model). In this study, we demonstrate that geldanamycin has very strong activities against herpes simplex virus type 2 in vitro and in vivo (mouse vagina model). In mouse vagina model, administration of geldanamycin suspension to vagina after virus infection protected the infected mice from death and increased the average survival days in a dose-dependent manner. Geldanamycin also significantly reduced virus shedding from mouse vagina. All geldanamycin-treated groups were statistically significant when compared with the infected control group. The high-dose group of geldanamycin (5.72 mg kg(−1)) was better than acyclovir group (2.86 mg kg(−1)). All geldanamycin vaginal administration mock-infected groups did not show significant body weight loss. Although geldanamycin has strong antiviral activities against various DNA and RNA viruses, geldanamycin is not suitable for systemic administration because of its high toxicity. We consider that geldanamycin is a candidate of topical usage for the treatment of herpes simplex virus type infections. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/ja.2012.67) contains supplementary material, which is available to authorized users.
has issue date	2012-08-22(xsd:dateTime)
bibo:doi	10.1038/ja.2012.67
bibo:pmid	22909975
has license	no-cc
sha1sum (hex)	2e3c22a76c5ea1315c7a7795ec55972a32747428
schema:url	https://doi.org/10.1038/ja.2012.67
resource representing a document's title	Geldanamycin, a ligand of heat shock protein 90, inhibits herpes simplex virus type 2 replication both in vitro and in vivo
has PubMed Central identifier	PMC7094714
has PubMed identifier	22909975
schema:publication	J Antibiot (Tokyo)
resource representing a document's body	covid:2e3c22a76c5ea1315c7a7795ec55972a32747428#body_text
is schema:about of	named entity 'LIGAND' named entity 'mouse' named entity 'mouse' named entity 'activities' named entity 'vagina' named entity 'average' named entity 'study' named entity 'ligand' named entity 'VAGINA' named entity 'STUDY' named entity 'TOPICAL' named entity 'ENCEPHALITIS' named entity 'DOSE-DEPENDENT' named entity 'ACTIVITIES' named entity 'IS A' named entity 'GROUPS' named entity 'LIGAND' named entity 'RNA VIRUSES' named entity 'REDUCED' named entity 'PREVIOUSLY' named entity 'DID' named entity 'BODY WEIGHT LOSS' named entity 'DEATH' named entity 'ADMINISTRATION' named entity 'INCREASED' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'IN VIVO' named entity 'GELDANAMYCIN' named entity 'AVERAGE' named entity 'BETTER' named entity 'GROUP' named entity 'IN VIVO' named entity 'VERY STRONG' named entity 'DNA' named entity 'CONTROL GROUP' named entity 'ITS' named entity '90%' named entity 'INFECTIONS' named entity 'STATISTICALLY SIGNIFICANT' named entity 'IN VITRO' named entity 'HERPES SIMPLEX VIRUS TYPE 2' named entity 'SURVIVAL' named entity 'SUSPENSION' named entity 'SUITABLE' named entity 'USAGE' named entity 'HEAT SHOCK PROTEIN 90' named entity 'HEAT SHOCK PROTEIN 90' named entity 'MODEL' named entity '282' named entity 'ANTIVIRAL' named entity 'TREATED' named entity 'CANDIDATE' named entity 'MG KG' named entity 'DAYS' named entity 'INFECTED' named entity 'VARIOUS' named entity 'HIGH-DOSE' named entity 'TREATMENT' named entity 'STRONG' named entity 'VIRUS INFECTION' named entity 'VIRUS TYPE' named entity 'GELDANAMYCIN' named entity 'REPLICATION' named entity 'COMPARED' named entity 'MICE' named entity 'SIGNIFICANT' named entity 'ACYCLOVIR' named entity 'VIRUS SHEDDING' named entity 'REPLICATION' named entity 'HERPES SIMPLEX VIRUS' named entity 'SYSTEMIC ADMINISTRATION' named entity 'INHIBITED' named entity 'HERPES SIMPLEX VIRUS TYPE 2' named entity 'CONSIDER' named entity 'VAGINAL' named entity 'IN VITRO' named entity '90%'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software